Sep 2026· Cancer Research· Vol 86, pp. B024-B024· 0 citations
TL;DR
It is demonstrated that senescent cancer-associated fibroblasts drive early-stage lymph node metastasis in pancreatic cancer through lactate-mediated metabolic-epigenetic rewiring, revealing a closed link between cellular senescence and PDAC metastasis.
Abstract
Lymph node metastasis (LNM) in early-stage PDAC predicts systemic dissemination and poor survival, yet its underlying mechanisms remain elusive. Here, we demonstrated that senescent cancer-associated fibroblasts (senCAFs) drive lymphatic remodeling and LNM in early-stage PDAC. Mechanistically, senCAFs increased glucose metabolism and lactate production, which activated lactylation-mediated serine metabolism to protect lymphatic endothelial cells from oxidative stress. Moreover, we discovered CCR4+ Tregs from the draining lymph nodes accumulated around lymphatic vessels, which established an immunosuppressive peri-lymphatic niche. High throughput drug screening determined selective clearance of senCAFs via chidamide, attenuated tumor progression and improved chemo-immunotherapeutic efficacy. We subsequently initiated a clinical trial (chidamide and nab-paclitaxel/gemcitabine plus anti-PD-1/CTLA-4) in metastatic PDAC patients and reported its preliminary promising results. Collectively, these findings reveal a closed link between cellular senescence and PDAC metastasis, offering the potential senolytic means to improve chemo-immunotherapy efficacy.
Tianxing Zhou. Senescent cancer-associated fibroblasts drive early-stage lymph node metastasis in pancreatic cancer through lactate-mediated metabolic-epigenetic rewiring [abstract]. In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_2):Abstract nr B024.
GSDMD dysregulation correlates with activated EMT and lymphangiogenic signaling, potentially facilitating tumor lymphatic dissemination, and is highlighted as a promising therapeutic candidate for restraining cervical cancer metastatic progression.
Fu-Feng Gao, Hang Yu, Hui-Can Guo et al.· Journal of Inflammation Rese...· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with 90% of patients developing resistance to standard chemotherapy, such as gemcitabine/paclitaxel protein-bound (GnP). PDAC tumors are characteristically immunosuppressive and fibrotic due to programs activated in tumor-associated macrophages (TA...
Debbie K. Ledezma, K. Gulay, Hervé Tiriac et al.· Cancer Research· 0 citations
Chemotherapy remains a cornerstone treatment for pancreatic ductal adenocarcinoma (PDAC), yet it paradoxically promotes metastatic recurrence. Elucidation of the underlying mechanisms mediating chemotherapy-induced metastasis could help identify improved combination treatment strategies. Here, we used a dormancy-tracki...
Shang-Heng Shi, Jing-Rui Yan, Yu Zhang et al.· Cancer Research· 0 citations
These findings uncover a CAF‐exosomal circFAD104 axis that reprograms glucose metabolism to drive TNBC progression via the circFAD104/MARCHF8/PGM1 pathway, highlighting its potential as a stroma‐targeted biomarker and prognostic predictor.
Lei Wang, Xiaoyan Li, Yi-Ran Liang et al.· Advancement of science· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is characterized by aggressive metastatic progression and poor clinical outcomes. During metastatic dissemination, detached tumor cells must overcome anoikis, a form of apoptosis induced by loss of extracellular matrix attachment. Although anoikis resistance is considered a criti...
Li-Zhi Lin, M. Bauden, Roland Andersson et al.· BMC Cancer· 0 citations
CAF-directed stromal priming as a strategy to enhance chemoimmunotherapy and warrant evaluation in randomized studies with integrated biomarker analyses are supported.
V. S. Kalluri, B. Bockorny, Evelio Perea Borobio et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.